BACKGROUND: Human IL-32 is a polyfunctional cytokine that was initially reported to inhibit HIV-1 infection. However, recent data suggest that IL-32 may enhance HIV-1 replication by activating the HIV-1 primary targets, CD4 T-cells. Indeed, IL-32 is expressed in multiple isoforms, some of which are proinflammatory, whereas others are anti-inflammatory. SETTING AND METHODS: Here, we aimed to determine the relative expression of IL-32 isoforms and to test their inflammatory nature and potential to induce HIV-1 production in latently infected cells from virologically suppressed HIV-infected individuals. IL-32 and other cytokines were quantified from plasma and supernatant of CD4 T-cells by ELISA. Transcripts of IL-32 isoforms were quantified by qRT-PCR in peripheral blood mononuclear cells. The impact of recombinant human IL-32 isoforms on HIV-1 transcription was assessed in CD4 T-cells from HIV-1cART individuals by qRT-PCR. RESULTS: All IL-32 isoforms were significantly upregulated in HIV-1cART compared to HIV individuals with IL-32β representing the dominantly expressed isoform, mainly in T-cells and NK-cells. At the functional level, although IL-32γ induced typical proinflammatory cytokines (IL-6 and IFN-γ) in TCR-activated CD4 T-cells, IL-32α showed an anti-inflammatory profile by inducing IL-10 but not IL-6 or IFN-γ. However, IL-32β showed a dual phenotype by inducing both pro- and anti-inflammatory cytokines. Interestingly, consistent with its highly pro-inflammatory nature, IL-32γ, but not IL-32α or IL-32β, induced HIV-1 production in latently infected CD4 T-cells isolated from combined antiretroviral therapy-treated individuals. CONCLUSIONS: Our data report on the differential expression of IL-32 isoforms and highlight the potential role of IL-32, particularly the γ isoform, in fueling persistent inflammation and transcription of viral reservoir in HIV-1 infection.
BACKGROUND:HumanIL-32 is a polyfunctional cytokine that was initially reported to inhibit HIV-1 infection. However, recent data suggest that IL-32 may enhance HIV-1 replication by activating the HIV-1 primary targets, CD4 T-cells. Indeed, IL-32 is expressed in multiple isoforms, some of which are proinflammatory, whereas others are anti-inflammatory. SETTING AND METHODS: Here, we aimed to determine the relative expression of IL-32 isoforms and to test their inflammatory nature and potential to induce HIV-1 production in latently infected cells from virologically suppressed HIV-infected individuals. IL-32 and other cytokines were quantified from plasma and supernatant of CD4 T-cells by ELISA. Transcripts of IL-32 isoforms were quantified by qRT-PCR in peripheral blood mononuclear cells. The impact of recombinant humanIL-32 isoforms on HIV-1 transcription was assessed in CD4 T-cells from HIV-1cART individuals by qRT-PCR. RESULTS: All IL-32 isoforms were significantly upregulated in HIV-1cART compared to HIV individuals with IL-32β representing the dominantly expressed isoform, mainly in T-cells and NK-cells. At the functional level, although IL-32γ induced typical proinflammatory cytokines (IL-6 and IFN-γ) in TCR-activated CD4 T-cells, IL-32α showed an anti-inflammatory profile by inducing IL-10 but not IL-6 or IFN-γ. However, IL-32β showed a dual phenotype by inducing both pro- and anti-inflammatory cytokines. Interestingly, consistent with its highly pro-inflammatory nature, IL-32γ, but not IL-32α or IL-32β, induced HIV-1 production in latently infectedCD4 T-cells isolated from combined antiretroviral therapy-treated individuals. CONCLUSIONS: Our data report on the differential expression of IL-32 isoforms and highlight the potential role of IL-32, particularly the γ isoform, in fueling persistent inflammation and transcription of viral reservoir in HIV-1 infection.
Authors: Elias A Said; Franck P Dupuy; Lydie Trautmann; Yuwei Zhang; Yu Shi; Mohamed El-Far; Brenna J Hill; Alessandra Noto; Petronela Ancuta; Yoav Peretz; Simone G Fonseca; Julien Van Grevenynghe; Mohamed R Boulassel; Julie Bruneau; Naglaa H Shoukry; Jean-Pierre Routy; Daniel C Douek; Elias K Haddad; Rafick-Pierre Sekaly Journal: Nat Med Date: 2010-03-07 Impact factor: 53.440
Authors: David Favre; Jeff Mold; Peter W Hunt; Bittoo Kanwar; P'ng Loke; Lillian Seu; Jason D Barbour; Margaret M Lowe; Anura Jayawardene; Francesca Aweeka; Yong Huang; Daniel C Douek; Jason M Brenchley; Jeffrey N Martin; Frederick M Hecht; Steven G Deeks; Joseph M McCune Journal: Sci Transl Med Date: 2010-05-19 Impact factor: 17.956
Authors: Anthony J Smith; Chad M Toledo; Stephen W Wietgrefe; Lijie Duan; Timothy W Schacker; Cavan S Reilly; Ashley T Haase Journal: J Immunol Date: 2011-04-27 Impact factor: 5.422
Authors: Alan T Rodriguez-Penney; Jennifer E Iudicello; Patricia K Riggs; Katie Doyle; Ronald J Ellis; Scott L Letendre; Igor Grant; Steven Paul Woods Journal: AIDS Patient Care STDS Date: 2013-01 Impact factor: 5.078
Authors: W Nicholas Haining; Debattama R Sen; Kathleen B Yates; Pierre Tonnerre; Genevieve E Martin; Ulrike Gerdemann; Rose Al Abosy; Dawn E Comstock; Sarah A Weiss; David Wolski; Damien C Tully; Raymond T Chung; Todd M Allen; Arthur Y Kim; Sarah Fidler; Julie Fox; John Frater; Georg M Lauer Journal: Nat Immunol Date: 2021-07-26 Impact factor: 25.606
Authors: Lesley R de Armas; Christina Gavegnano; Suresh Pallikkuth; Stefano Rinaldi; Li Pan; Emilie Battivelli; Eric Verdin; Ramzi T Younis; Rajendra Pahwa; Siôn L Williams; Raymond F Schinazi; Savita Pahwa Journal: Front Immunol Date: 2021-08-31 Impact factor: 7.561
Authors: Pablo Villoslada-Blanco; Patricia Pérez-Matute; María Íñiguez; Emma Recio-Fernández; Pilar Blanco-Navarrete; Luis Metola; Valvanera Ibarra; Jorge Alba; María de Toro; José A Oteo Journal: Infect Dis Ther Date: 2022-05-26
Authors: Mohamed El-Far; David B Hanna; Madeleine Durand; Etienne Larouche-Anctil; Mohamed Sylla; Carl Chartrand-Lefebvre; Guy Cloutier; Jean Philippe Goulet; Seble Kassaye; Roksana Karim; Jorge R Kizer; Audrey L French; Stephen J Gange; Jason M Lazar; Howard N Hodis; Jean-Pierre Routy; Petronela Ancuta; Nicolas Chomont; Alan L Landay; Robert C Kaplan; Cécile L Tremblay Journal: J Acquir Immune Defic Syndr Date: 2021-10-01 Impact factor: 3.771